|[April 16, 2014]
Agenus to Host Annual Meeting of Stockholders
LEXINGTON, Mass. --(Business Wire)--
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to
its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on
Wednesday, April 23, 2014. The meeting will be held at the company's
headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration
for attendees starts at 4:30 p.m. ET.
The company will also broadcast the meeting via a virtual stockholder
meeting. Instructions on how to participate and demonstrate proof of
stock ownership are posted at www.virtualshareholdermeeting.com/Agenus2014.
A live webcast will be accessible from the company's website at www.agenusbio.com/webcast/
and will be archived and available for replay within twenty-four hours
after the meeting.
Agenus is an immuno-oncology company developing
a portfolio of checkpoint modulators, heat shock protein vaccines and
adjuvants. Agenus' checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1. The company's proprietary discovery
engine Retrocyte Display® is used to generate fully human
therapeutic antibody drug candidates. The Retrocyte Display platform
uses a high-throughput approach incorporating full-length IgG format
human antibody libraries expressed in mammalian B-lineage cells. Agenus'
heat shock protein vaccines for cancer and infectious disease are in
Phase 2 studies. The company's QS-21 Stimulon® adjuvant
platform is extensively partnered with GlaxoSmithKline and Janssen, and
includes several candidates in Phase 3 trials. Among Agenus and its
partners, 22 programs are in clinical development. For more information,
please visit www.agenusbio.com,
or connect with the company on Facebook,
QS-21 Stimulon and Retrocyte Display are registered trademarks of Agenus
and its subsidiaries.
[ Back To TMCnet.com's Homepage ]